Medical Advocates
HIV Drug Monitoring
  Main Page
New and Noteworthy
 Guidelines
 General Reports
 Efficacy
Economics
 Drug-Specific Studies
 Genotype Tests
 Phenotype Tests
 US Reimbursement for Drug Resistance Testing



 
Home Page Main New/Newsworthy        
This web page is best viewed by using INTERNET EXPLORER
Last Update:  May 11, 2008
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
New and Noteworthy
     
January 2008
 
General Reports
       
Books
 
  FULL-TEXT BOOK CHAPTER
HIV Resistance Testing
Wolf E
HIV Medicine-2003 Hoffmann C, Kamps, BS (editors) Amedeo Group 2003
On-Line Book

Journal Papers, Abstracts, and Commentaries
 
 
Clinically Important Drug Interactions Potentially Involving Mechanism-based Inhibition of
Cytochrome P450 3A4 and the Role of Therapeutic Drug Monitoring.
Zhou SF, Xue CC, Yu XQ, et al 
Ther Drug Monit. 2007 Dec;29(6):687-710.
 Abstract
 
Incorporating novel virologic tests into clinical practice.
Daar ES.
 Top HIV Med. 2007 Aug-Sep;15(4):126-9.
Abstract
 
The influence of antiretroviral-resistance tests on treatment effectiveness in patients
with HIV and virological failure.
Gamero Martin-Granizo A, Martinez Roca C, Margusino Framinan L, Martin Herranz I.
Farm Hosp. 2007 Mar;31(1):23-29
 Abstract
 
Antiretroviral drug resistance testing.
Sen S, Tripathy SP, Paranjape RS.  
J Postgrad Med. 2006 Jul-Sep;52(3):187-93.
Abstract
 
Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic
drug monitoring.
Nettles RE, Kieffer TL, Parsons T, ey al
Clin Infect Dis. 2006 Apr 15;42(8):1189-96.
 Abstract
 
Therapeutic Drug Monitoring and Human Immunodeficiency Virus (HIV) Antiretroviral Therapy.
Justesen US.
 Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):20-31.
 Abstract
 
Antiretroviral Drug Resistance and Resistance Testing.
Gallant JE
Top HIV Med. 2005 Dec/Jan;13(5):138-142.
 Abstract
 
Utilization and Access to Antiretroviral Genotypic Resistance Testing and Results Within the
US Department of Veterans Affairs.
Goetz MB, Holodniy M, Poulton JS, et al
J Acquir Immune Defic Syndr. 2006 Jan 1;41(1):59-62
 Abstract
 
Genotypic and phenotypic resistance testing of HIV-1 in routine clinical care.
Hirsch HH, Drechsler H, Holbro A, et al
Eur J Clin Microbiol Infect Dis.2005 Nov;24(11):733-8.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
 Should Resistance Testing Be Performed for Treatment-Naive HIV-Infected Patients? A Cost-
Effectiveness Analysis.
Sax PE, Islam R, Walensky RP, et al  
Clin Infect Dis. 2005 Nov 1;41(9):1316-23.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Clinical benefit of interventions driven by therapeutic drug monitoring.
Rendon A, Nunez M, Jimenez-Nacher
HIV Med. 2005 Sep;6(5):360-5
 Abstract
 
TDM: Therapeutic Drug Measuring or Therapeutic Drug Monitoring?
Droste JA, Koopmans PP, Hekster YA, Burger DM.
Ther Drug Monit. 2005 Aug;27(4):412-6.
 Abstract
 
Prevalence of Antiretroviral Drug Resistance Mutations in Chronically HIV-Infected,
Treatment-Naive Patients: Implications for Routine Resistance Screening before
Initiation of Antiretroviral Therapy.
Novak RM, Chen L, Macarthur RD, et al 
Clin Infect Dis. 2005 Feb 1;40(3):468-74.
 Abstract

Limited benefit of antiretroviral resistance testing in treatment-experienced patients: a
meta-analysis.
Panidou ET, Trikalinos TA, Ioannidis JP.
AIDS. 2004 Nov 5;18(16):2153-2161.
Abstract

Benefits and limitations of testing for resistance to HIV drugs.
Richman DD. 
J Antimicrob Chemother. 2004 Mar 10
 Abstract

Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type
1-infected patients: results of the clinical efficacy of resistance testing trial.
Wegner SA, Wallace MR, Aronson NE, et al
Clin Infect Dis. 2004 Mar 1;38(5):723-30
 Abstract
 
Impact of different HIV resistance interpretation by distinct systems on clinical utility of
resistance testing.
De Luca A, Perno CF. 
Curr Opin Infect Dis. 2003 Dec;16(6):573-80.
Abstract
 
Update on HIV resistance and resistance testing.
Sebastian J, Faruki H .
Med Res Rev. 2004 Jan;24(1):115-25.
 Abstract

FULL-TEXT PDF ARTICLE
 Questions to and Answers from the International AIDS Society-USA Resistance
Testing Guidelines Panel.
Hirsch MS, Brun-Vezinet F, Clotet B, et al
 Top HIV Med. 2003 Jul-Aug;11(4):150-4.
Paper
 
Antiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency
Virus Type 1: 2003 Recommendations of an International AIDS Society-USA Panel.
Hirsch MS, Brun-Vezinet F, Clotet B, et al
Clin Infect Dis. 2003 Jul 1;37(1):113-28
 Abstract

Therapeutic drug monitoring in the treatment of HIV-infection.
Gerber JG, Acosta EP
J Clin Virol. 2003 Jul;27(2):117-28.
Abstract
 

Conference Reports, Abstracts, and Posters
 
 
POSTER
 Approaches to the analysis of therapeutic drug monitoring data.
Gibbons S, Back D, Boffito M, et al
(8th Int Congress on Drug Therapy in HIV Infection)
 PDF Poster    Abstract
 
Therapeutic drug monitoring (TDM): is it of clinical utility in HIV+ pregnant women?
 RJ Caswell, S Doshi, SH Khoo, et al
 (8th Int Congress on Drug Therapy in HIV Infection)
 Abstract
 
Drug resistance testing and therapeutic drug monitoring in HIV-1 infection
 DR Kuritzkes
(8th Int Congress on Drug Therapy in HIV Infection)
 Abstract
 
The place for therapeutic drug monitoring
M Boffito
(8th Int Congress on Drug Therapy in HIV Infection)
 Abstract
 
The place of drug resistance testing in the clinical management of HIV
 A Wensing
(8th Int Congress on Drug Therapy in HIV Infection)
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
POSTER
 White Coat Compliance Patterns Make Therapeutic Drug Monitoring a Potentially Unreliable Tool
for Assessing Long-term Drug Exposure
TJ Podsadecki, B Vrijens, E Tousset, et al 
(13 CROI)
 PDF Poster
 
Improved ART Exposure with Therapeutic Drug Monitoring
B Best, M Witt, M Goicoechea, C Kemper, et al 
Abstract
 
Clinical Cutoffs Enhance Prediction of Treatment Response
B. WINTERS, A. RINEHART, L. BACHELER; et al 
 (45 ICAAC)
 Abstract
 
Determinants of the Need for Therapeutic Drug Monitoring: Rates and Predictors
from CCTG 578
R Haubrich, B Best, M Witt. et al;
(12 CROI)
 Abstract

The Benefit of Treatment Interventions Driven by Therapeutic Drug Monitoring
A L Rendon, M Nunez, D Gonzalez-Requena, et al 
(11 CROI)
 Abstract
 
  POSTER
Clinician knowledge and attitudes towards genotypic testing
 C Salama, et al.
H Walter, M Helm, R Ehret, er al.
(XII International HIV Drug Resistance Workshop)
 PDF Poster
 
Predictive value of drug resistance interpretation systems and therapeutic drug
monitoring or virological therapy response to salvage therapy
H Walter, M Helm, R Ehret, er al.
(XII International HIV Drug Resistance Workshop)
 Abstract

     1st European HIV Drug Resistance Workshop
 
  Estimating effective drug combinations against drug-resistant mutants from genotypes
N Beerenwinkel, T Lengauer, M Däumer, et al 
(1st European HIV Drug Resistance Workshop) _
 Abstract
 
  POSTER
Development of an HIV Drug Interactions and Antiretroviral Therapeutic Drug Monitoring
Registry
GD Morse, P Smith, R DiCenzo, et al.
(3rd International Workshop on Clinical Pharmacology of HIV Therapy)
PDF Poster
General Efficacy Studies
       
Journal Papers, Abstracts, and Commentaries
 
 
Comparison of the COBAS TAQMANtrade mark HIV-1 HPS with VERSANT HIV-1 RNA 3.0
Assay (bDNA) for plasma RNA quantitation in different HIV-1 subtypes.
Gomes P, Palma AC, Cabanas J,
 J Virol Methods. 2006 May 2;
 Abstract
 
Discordance between Viral Loads Determined by Roche COBAS AMPLICOR Human
Immunodeficiency Virus Type 1 Monitor (Version 1.5) Standard and Ultrasensitive Assays
Caused by Freezing Patient Plasma in Centrifuged Becton-Dickinson Vacutainer Brand
Plasma Preparation Tubes.
Salimnia H, Moore EC, Crane LR, et al   
J Clin Microbiol. 2005 Sep;43(9):4635-9.
 Abstract
 
Comparison of the Sensitivities and Viral Load Values of the AMPLICOR HIV-1
MONITOR Version 1.0 and 1.5 Tests.
Caliendo AM, Ingersoll J, Green AM, et al
J Clin Microbiol. 2004 Nov;42(11):5392-5393.
 Abstract
 
Performance of the VERSANT((R)) HIV-1 Resistance Assays (LiPA) for detecting drug
resistance in therapy-naive patients infected with different HIV-1 subtypes.
Derdelinckx I, Van Laethem K, Maes B. et al
FEMS Immunol Med Microbiol. 2003 Nov 28;39(2):119-124.
 Abstract
 

Conference Reports, Abstracts, and Posters

  Prospective Trial to Evaluate how Therapeutic Drug Monitoring of Protease Inhibitors Increases
Virologic Success and Tolerance of HAART (COPHAR 2 - ANRS 111 trial)
FMX Duval, E Rey, et al
(12 CROI)
Abstract
Economics
       

Journal Papers, Abstracts, and Commentaries

 
A WEEK-IN-REVIEW FEATURED REPORT
Should Resistance Testing Be Performed for Treatment-Naive HIV-Infected Patients? A Cost-
Effectiveness Analysis.
Sax PE, Islam R, Walensky RP, et al  
Clin Infect Dis. 2005 Nov 1;41(9):1316-23.
 Abstract

Assessing resistance costs of antiretroviral therapies via measures of future drug
options.
Jiang H, Deeks SG, Kuritzkes DR 
J Infect Dis. 2003 Oct 1;188(7):1001-8.
Abstract
 

Home Page Main New/Newsworthy Home Page      

HIV Drug Monitoring Main Page